View : 19 Download: 0

Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: Results of the Korean Multiple Myeloma Working Party (KMMWP)

Title
Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: Results of the Korean Multiple Myeloma Working Party (KMMWP)
Authors
Eom H.-S.Kim Y.-K.Chung J.-S.Kim K.Kim H.J.Kim H.Y.Jin J.-Y.Do Y.-R.Oh S.-J.Suh C.Seong C.-M.Kim C.S.Lee D.S.Lee J.H.
Ewha Authors
성주명
SCOPUS Author ID
성주명scopus
Issue Date
2010
Journal Title
Annals of Hematology
ISSN
0939-5555JCR Link
Citation
vol. 89, no. 5, pp. 489 - 497
Indexed
SCI; SCIE; SCOPUS WOS scopus
Abstract
Bortezomib (VELCADE®), thalidomide and dexamethasone (VTD), as well as melphalan, prednisolone, and thalidomide (MPT) therapy, are highly effective in patients with multiple myeloma. We evaluated the responses and survival times of 35 patients treated with VTD followed by MPT. All patients were newly diagnosed and non-transplantation candidates. Patients received six cycles of VTD, which were followed by eight cycles of MPT. Approximately 97% of patients exhibited early responses to therapy, as early as the second cycle of VTD. Thirty percent of the responses were high quality, which was defined as a complete response (CR), a near-CR or a very good partial response. High-risk patients were defined as patients with any of the following aberrations: del(13), t(4;14), or del(17p). The remaining patients were defined as standard risk. Eleven high-risk patients showed 100% response rates, including 91% high-quality responses. In contrast, 13 standard-risk patients exhibited 92% response rates, including 61% high-quality responses. The overall 2-year survival rates were 60% in high-risk patients and 85% in standard-risk patients, which was not significantly different. As a first-line therapy, VTD followed by MPT has the potential to provide high-quality responses with durable remission among elderly and high-risk patients (clinicaltrials.gov identifier: NCT00320476). © 2009 Springer-Verlag.
DOI
10.1007/s00277-009-0871-y
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE